Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V)

Epilepsy Research

Volumn 43, Issue 1, 2001, Pages 11-58

  Bialer, M ^a   Johannessen, S I ^b   Kupferberg, H J ^c   Levy, R H ^d   Loiseau, P ^e   Perucca, E ^f  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b National Center for Epilepsy   (Norway)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HÔPITAL PELLEGRIN   (France)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Clinical trials; Conference; Drug development; Epilepsy; Pharmacology

Indexed keywords

1 (4 CHLOROPHENYL) 4 MORPHOLINO 3 IMIDAZOLIN 2 ONE; 4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; ISOVALERAMIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; REMACEMIDE; RETIGABINE; RUFINAMIDE; SAFINAMIDE; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ARTICLE; ATAXIA; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EPILEPSY; HUMAN; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; VAGUS NERVE STIMULATION;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; HUMANS; NEUROLOGY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0035200133     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00171-6     Document Type: Article

References (198)

1. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
2. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death
3. Guidelines for prescribing vigabatrin in children has been revised
4. Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicenter, double-blind, placebo-controlled study
5. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms
6. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices
7. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices
8. Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: A rare complication of intraoperative device testing
9. Zonisamide efficacy and dose response
10. Topiramate relieves refractory intercostal neuralgia
11. Oxcarbazepine placebo-controlled dose-ranging trial in refractory partial epilepsy
12. Oxcarbazepine: Pharmacokinetics interactions and their clinical relevance
13. Gestational outcomes in patients with epilepsy receiving vagus nerve stimulation
14. Pregabalin add-on trial: A double-blind, multicenter study in patients with partial epilepsy
15. Oxcarbazepine monotherapy for partial-onset seizures: A multicenter, double-blind, clinical trial
16. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference
17. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV)
18. Dopaminergic transplants in experimental parkinsonism: Cellular mechanisms of graft-induced functional recovery
19. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles
20. The disposition of valproyl glycinamide and valproyl glycine in rats
21. Cost-benefit of vagus nerve stimulation for refractory epilepsy
22. Muticentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
23. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy
24. Gabapentin versus lamotrigine monotherapy: A double-blind comparison
25. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
26. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicenter randomised double-blind study
27. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures
28. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects
29. A geriatric pharmacokinetic evaluation of rufinamide
30. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children
31. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs
32. Pediatric dosing recommendations of lamotrigine based on a population pharmacokinetic model
33. Topiramate as add-on treatment for patients with bipolar mania
34. Potential antiepileptic drugs. Remacemide hydrochloride
35. Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat
36. Enhanced recognition memory following vagus nerve stimulation in human subjects
37. Absence of visual field defects in patients taking tiagabine
38. Long-term use of Gabitril (tiagabine HCI) monotherapy in pediatric patients
39. Topiramate as a novel treatment for essential tremor
40. A double-blind placebo controlled cross-over study of remacemide hydrochloride as adjunctive therapy in patients with refractory epilepsy
41. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: Prediction of clinical response
42. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures
43. Stable weight during lamotrigine therapy: A review of 32 studies
44. A mechanistic approach to understanding species differences in felbamate bioactivation: Relevance to drug-induced idiosyncratic reactions
45. No clinically significant effect of topiramate on haloperidol plasma concentration
46. No significant effect of topiramate on lithium serum concentration
47. ++ model in the hippocampal slice preparation
48. Placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children
49. Electroretinographic changes are not associated with loss of visual function in pediatric epileptic patients following treatment with vigabatrin
50. A double-blind randomised trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura
51. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study
52. Preclinical evaluation of PNU-I51774E as a novel anticonvulsant
53. Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys
54. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women
55. Review of US clinical trials of zonisamide in treatment of refractory partial-onset seizures
56. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats
57. Fosphenytoin (Cerebyx) in status epilepticus: Safety, tolerance, and pharmacokinetics
58. Stability of Fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes
59. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
60. Pregabalin adjunctive therapy in patients with partial seizures
61. An active control trial of lamotrigine monotherapy for partial seizures
62. Topiramate monotherapy: Randomized controlled trial in patients with recently diagnosed localization-related epilepsy
63. Adjunctive therapy with oxcarbazepine in children with partial seizures
64. Treatment of infantile spasms: Results of a population-based study with vigabatrin as the first drug for spasms
65. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders
66. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study
67. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine
68. Neuroprotective effect of larnotrigine in perforant pathway stimulation model of status epilepticus in rat
69. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
70. Progressive myoclonus epilepsy treated with zonisamide
71. Retigabine (D-23129) strongly reduces repetitive firing in rat entorhinal cortex
72. Treatment of bipolar depression with topiramate
73. Valproate-related endocrine risks in women with epilepsy: A multicenter study
74. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
75. Long-term survival of fetal porcine lateral ganglionic eminence cells in the hippocampus of rats
76. Remacemide hydrochloride (300 mg, 600 mg, 800 mg/day) efficacy and safety versus placebo in patients with refractory epilepsy
77. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
78. Evaluation of rufinamide, a novel anticonvulsant, for potential drug interactions in vitro
79. D-23129: A new anticonvulsant compound
80. Potentially reactive cyclic carbarnate metabolite of the antiepileptic drug felbarnate produced by human liver tissues in vitro
81. Formation and reactivity of cyclic carbarnate metabolite (CCMF) of the antiepileptic drug felbamate (FBM) in human liver tissue in vitro
82. Switch to monotherapy with Lamictal compared to VPA
83. Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat
84. Tiagabine in the management of painful diabetic neuropathy. Annual Meeting of the American Pain Society, 21-22 October 1999
85. Evidence for a unique profile of levetiracetarn in rodent models of seizures and epilepsy
86. Fosphenytoin: Pharmacokinetics and administration
87. Fosphenytoin safety and pharmacokinetics in pediatrics patients
88. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures
89. Valproate-related endocrine risks in women with epilepsy: A multicenter study
90. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy
91. Recovery of visual field constriction following discontinuation of vigabatrin
92. Vigabatrin: Reversibility of severe concentric visual field defects after early detection and drug withdrawal - A case report
93. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and oplithalmologic findings
94. Efficacy and tolerability of tiagabine in infantile spasms
95. Preliminary, open-label study of topiramate in rapid cycling in bipolar women
96. Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients
97. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group
98. Mutual pharmacokinetic interactions between remacemide and carbamazepine and phenytoin but not sodium valproate in epileptic patients
99. Mutual interaction between remacemide hydrochloride and carbamazepine: Two drugs with active metabolites
100. Mutual interaction between remacemide hydrochloride and phenytoin
101. Gabapentin as add-on therapy for refractory partial epilepsy: Results of five placebo-controlled trials
102. International evaluation of zonisamide efficacy
103. Safety of tiagabine: Summary of 53 trials
104. Psychiatric adverse events during vigabatrin therapy
105. Clinical pharmacology and pharmacokinetics of oxcarbazepine
106. Antiepileptogenic effects of the novel anticonvulsant levetiracetarn (ucbL059) in the kindling model of temporal lobe epilepsy
107. Aspiration: A potential complication to vagus nerve stimulation
108. Non-epileptic uses of gabapentin
109. PN-LJ-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat
110. Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures
111. Use of topiramate, a new antiepileptic as a mood stabilizer
112. Zonisamide: Pharmacology and clinical efficacy in epilepsy
113. Lamotrigine adjunctive therapy in patients with mental retardation and refractory epilepsy
114. Rash in adult and pediatric patients treated with lamotrgiine
115. Weight gain associated with valproate monotherapy in patients with epilepsy: An interim analysis of a randomized, double-blind comparative clinical trial with larnotrigine
116. Antiepileptic therapy and the risk of severe cutaneous adverse reactions (SCAR)
117. The anticonvulsant zonisamide scavenges free radicals
118. Gabapentin
119. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05
120. Remacemide
121. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group
122. DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease
123. The novel antiepileptic drug levetiracetarn (ucbL059) appears to act via a specific binding site in CNS membranes
124. Efficacy and safety of rufinamide in patients with refractory epilepsy
125. Classification of compounds for prevention of NMDLA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro
126. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
127. Felbamate: 1997 update
128. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives
129. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta
130. Potential role of topiramate in relief of neuropathic pain
131. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of Topamax (topiramate) in the prophylactic treatment of migraine
132. Formalin-evoked activity in identified primary afferent fibers: Systemic lidocaine suppresses phase-2 activity
133. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy
134. Oxcarbazepine and intractable trigeminal neuralgia
135. AWD 131-138
136. AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: A comparison with diazepam and buspirone
137. Effect of the anticonvulsant retigabine in neuropathic pain models
138. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
139. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites
140. + channels in neuronal cells
141. + channel opening effect of the anticonvulsant retigabine in PC12 cells
142. The novel anticonvulsant retigabine activates M-currents in chinese hamster ovary-cells transfected with human KCNQ2/3 subunits
143. AWD 131-138 antagonizes the effect of corticotrophin releasing factor in locus coeruleus neurones in murine brain stem slices
144. Vagus nerve stimulation (VNS) for treatment-resistant depression: A multicenter study
145. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during the first weeks of antiepileptic therapy: A case-control study
146. Tiagabine therapy for complex partial seizures: A dose-frequency study
147. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy
148. Oxcarbazepine (Trileptal) effect on serum sodium
149. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound
150. Is the devil we know the lesser of the evils? Vigabatrin and visual fields
151. Safety and efficacy of tiagabine HCI monotherapy in the treatment of partial seizures: High dose versus low dose
152. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures
153. Chronic stimulation of the left vagal nerve in children: Effect on swallowing
154. Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial
155. Anticonvulsant profile of CGP33 101 in animals
156. Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action
157. Rufmamide (CGP33101): Broad anticonvulsant spectrum and excellent tolerability in rodents
158. Moderate loss of function of cyclic-AMP modulated KCNQ2/KCNQ3 K' channels causes epilepsy
159. Transplantation of embryonic porcine mesencephalic tissue in patients with PD
160. Efficacy evaluation of AD-810 (zonisamide). Double-blind study comparing with carbarnazepine
161. The novel anticonvulsant topiramate is anti-allodynic in a rat model of neuropathic pain
162. Safety of zonisamide in Japanese children
163. Status epilepticus and tiagabine therapy: Review of safety and epidemiologic considerations
164. The necessity of adjusting the dosage of zonisamide when coadministered with other antiepileptic drugs
165. Topiramate in migraine prophylaxis: A pilot study
166. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy
167. Structure-pharmacokinetic-pharmacodynamic relationships of the new antiepileptic drug valproyl glycinamide
168. Role of topiramate for refractory migraine prophylaxis: A retrospective pilot study
169. Retigabine suppresses epileptiforin activity in human neocortical slice preparations
170. The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats
171. Zonisamide monotherapy in newly diagnosed infantile spasms
172. Ventricular asystole during vagus nerve stimulation for epilepsy in humans
173. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models
174. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate
175. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration
176. Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids
177. The synthesis, in vitro reactivity and evidence for formation in humans of 5-phenyl-1,3-oxazinine-2,4-dione-a metabolite of felbamate
178. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures
179. AWD 131-138: A derivative of a series of imidazolinones with anticonvulsant activity
180. Anticonvulsant activity of AWD 131-138 in genetic animal models of epilepsy
181. Tiagabine for complex partial seizures
182. Visual field constriction in children treated with vigabatrin
183. Efficacy of topiramate in migraine prophylaxis: A retrospective chart analysis
184. Lamotrigine vs. phenytoin for treatment of status epilepticus: Comparison in an experimental model
185. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
186. Pharmacokinetics (PK) and pharmacodynamics of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock
187. Topiramate-treated cluster headache
188. Anticonvulsant profile of NPS 1776: A broad-spectrum anticonvulsant
189. Characteristics of a unique visual field defect attributed to vigabatrin
190. High dose gabapentin in refractory partial epilepsy: Clinical observations in 50 patients
191. Factors influencing the incidence of lamotrigine-related skin rash
192. Zonisamide dosing in pediatric patients with epilepsy
193. Treatment of infantile spasms with zonisamide
194. Evaluation of the antiepileptic drug AWD 131-138 for reinforcing and discriminative stimulus effects
195. Once-daily versus twice-daily vigabatrin: Is there a difference? The results of a double-blind pilot study